Gilead announces completion of marketing authorization in Japan for Yescarta

Kite Pharma, a Gilead company, announced that the marketing authorization in Japan for Yescarta, a chimeric antigen receptor, or CAR, T-cell therapy, has been transferred from Daiichi Sankyo to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences.